A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

NCT05703516 · clinicaltrials.gov ↗

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

OTHER: Capmatinib

Sponsor

Novartis Pharmaceuticals